e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Anti-infective treatment and resistance in respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Factors associated with compliance with palivizumab treatment in the Canadian rSV evaluation study for synagis (CARESS) registry (32005-2011)
I. Mitchell, B. Paes, A. Li, K. Lanctot (Hamilton, Canada)
Source:
Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Session:
Anti-infective treatment and resistance in respiratory infections
Session type:
Poster Discussion
Number:
4371
Disease area:
Paediatric lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Mitchell, B. Paes, A. Li, K. Lanctot (Hamilton, Canada). Factors associated with compliance with palivizumab treatment in the Canadian rSV evaluation study for synagis (CARESS) registry (32005-2011). Eur Respir J 2012; 40: Suppl. 56, 4371
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Risk factors that determine time to first RSV hospitalization in CARESS: The Canadian registry of palivizumab (2005-2011)
Source: Annual Congress 2012 - Epidemiology of various respiratory diseases
Year: 2012
RSV hospitalization in Down syndrome in the Canadian Registry of Synagis (CARESS) following prophylaxis (2006-2011)
Source: Annual Congress 2012 - New insights into respiratory infections in children
Year: 2012
CARESS: The Canadian registry of palivizumab (2005-2010)
Source: Annual Congress 2011 - Paediatric respiratory infection: signs, symptoms and sequelae
Year: 2011
An assessment of the use of palivizumab over 12 years from a Canadian Registry (CARESS).
Source: International Congress 2019 – New insights into childhood infections: from viral bronchiolitis to bronchiolitis obliterans
Year: 2019
RSV hospitalization in cystic fibrosis in the Canadian registry of palivizumab (CARESS) following prophylaxis (2005-2012)
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013
RSV hospitalization in infants with neuromuscular disease in the Canadian registry of palivizumab after prophylaxis (2005-2012)
Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma
Year: 2013
Drug treatment in a German real-life COPD cohort (DACCORD)
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Changing incidence of pneumonia diagnosis in UK primary care from 2002-2017: Population-based cohort study
Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment
Year: 2019
Respiratory syncytial virus (RSV) hospitalization in infants with congenital airway anomalies (CAA) in the canadian registry of palivizumab (CARESS) after prophylaxis (2005-2012)
Source: International Congress 2014 – Paediatric epidemiology: new insights into primary ciliary dyskinesia, prematurity and bronchiolitis
Year: 2014
Ten-year projected outcomes associated with increased use of triple therapies in UK patients with COPD using the COPD Health Outcome Policy and INtervention (CHOPIN) model
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021
Comorbidity and mortality in Swedish asthma patients 2006 – 2013 - An observational register study (PACEHR)
Source: International Congress 2016 – Asthma management in primary care
Year: 2016
The Northjutland COPD prevention study (NCPS)
Source: Eur Respir J 2006; 28: Suppl. 50, 447s
Year: 2006
Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK)
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
National trends in utilization and outcomes of percutaneous coronary intervention (PCI) among patients with and without COPD in Spain (2001-2011)
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
The Northjutland COPD follow-up prevention study (NCPS)
Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD
Year: 2010
Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis
Year: 2021
Real-world effects of tezacaftor/ivacaftor (TEZ/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data
Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis
Year: 2021
Underlying clinical conditions and invasive pneumococcal disease (IPD) in adults in Spain (ODIN study, 2010-2012)
Source: Annual Congress 2013 –Recent developments in pneumonia
Year: 2013
Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept